Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment

被引：0
|
作者：
Alexandros A. Drosos
Eleftherios Pelechas
Evripidis Kaltsonoudis
Paraskevi V. Voulgari
机构：
[1] University of Ioannina,Rheumatology Clinic, Department of Internal Medicine, Medical School
来源：
Current Rheumatology Reports | 2020年 / 22卷
关键词：
csDMARDs; bDMARDs; Triple therapy; Cost-effectiveness; Work productivity; Quality of life;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Therapeutic Options and Cost-Effectiveness for Rheumatoid Arthritis Treatment
    Drosos, Alexandros A.
    Pelechas, Eleftherios
    Kaltsonoudis, Evripidis
    Voulgari, Paraskevi V.
    CURRENT RHEUMATOLOGY REPORTS, 2020, 22 (08)
  • [2] A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis
    Choi, HK
    Seeger, JD
    Kuntz, KM
    ARTHRITIS AND RHEUMATISM, 2000, 43 (10): : 2316 - 2327
  • [3] COST-EFFECTIVENESS OF BIOLOGIC THERAPEUTIC SEQUENCES FOR RHEUMATOID ARTHRITIS IN THE UK
    Emery, P.
    Taylor, P.
    Isaacs, J. D.
    Drost, P.
    Dupont, D.
    Beresniak, A.
    VALUE IN HEALTH, 2009, 12 (07) : A439 - A439
  • [4] THE COST-EFFECTIVENESS OF ALTERNATIVE TREATMENT SEQUENCES IN RHEUMATOID ARTHRITIS
    Trueman, D.
    Bird, A.
    Mumby-Croft, J.
    VALUE IN HEALTH, 2014, 17 (03) : A48 - A48
  • [5] COST-EFFECTIVENESS ANALYSIS OF GOLIMUMAB FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
    Desai, R. J.
    Rao, J.
    Biddle, A. K.
    VALUE IN HEALTH, 2012, 15 (04) : A39 - A39
  • [6] A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis in korea
    Sung, YK
    Choi, CB
    Park, EJ
    Kim, JJ
    Park, SJ
    Lee, EK
    Bae, SC
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S236 - S236
  • [7] A cost-effectiveness analysis of treatment options for patients with methotrexate (MTX)-naive rheumatoid arthritis.
    Choi, HK
    Seeger, JD
    Kuntz, KM
    ARTHRITIS AND RHEUMATISM, 2000, 43 (09): : S389 - S389
  • [8] Tocilizumab in the Treatment of Rheumatoid Arthritis: A Cost-Effectiveness Analysis in the UK
    Alex Diamantopoulos
    A. Finckh
    T. Huizinga
    D. K. Sungher
    L. Sawyer
    D. Neto
    F. Dejonckheere
    PharmacoEconomics, 2014, 32 : 775 - 787
  • [9] Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice
    Virkki, L. M.
    Konttinen, Y. T.
    Peltomaa, R.
    Suontama, K.
    Saario, R.
    Immonen, K.
    Jantti, J.
    Tuomiranta, T.
    Nykanen, P.
    Hameenkorpi, R.
    Heikkila, S.
    Isomaki, P.
    Nordstrom, D.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (06) : 1059 - 1066
  • [10] The Cost-Effectiveness of Biologics for the Treatment of Rheumatoid Arthritis: A Systematic Review
    Joensuu, Jaana T.
    Huoponen, Saara
    Aaltonen, Kalle J.
    Konttinen, Yrjo T.
    Nordstrom, Dan
    Blom, Marja
    PLOS ONE, 2015, 10 (03):
12345